Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
wet AMD
Pharma
Roche's Vabysmo shows durability in retinal vein occlusion
Roche has presented data that show Vabysmo can maintain visual gains in RVO with a dosing duration stretched to as long as once every four months.
Kevin Dunleavy
Oct 10, 2023 10:21am
Battling Roche's Vabysmo, Regeneron's Eylea shows durability
Aug 10, 2023 11:44am
Roche opens up the world with new ad for Vabysmo
Apr 25, 2023 4:50pm
FDA grants priority review to Regeneron's high-dose Eylea filing
Feb 23, 2023 10:05am
Roche's COVID drugs tumble $1B as new products disappoint
Oct 18, 2022 11:05am
Regeneron's souped-up Eylea data awes analysts
Sep 9, 2022 9:54am